Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Baxter International (BAX)

NYSE: BAX · Medical Devices · Deerfield, IL

Our rating: Positive

Call changed from Neutral to Positive at $23.00, moderate conviction, October 30, 2026.

Breaks if: The positive call rests on free cash flow holding near current levels. It breaks if reported free cash flow falls below $600M in either of the next two annual reporting periods — a roughly 30% decline that would signal real cash deterioration rather than a non-cash accounting drag, and would remove the primary support for the valuation argument.

Key figures

Market value$13.1B
Revenue, last 12 months$11.6B
Net income, last 12 months−$723M
Free cash flow, last 12 monthsn/a
Price to earningsn/a
Free cash flow yieldn/a
Dividend yield0.2%
Operating margin−1.9%
Return on equity−10.5%
Beta to the S&P 5000.84
Volatility, annualized40.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$3.0B5.0%$0.57n/a
June 30, 2026$3.0B5.3%$0.24n/a
March 31, 2026$2.7B2.9%$-0.03n/a
December 31, 2025$3.0B8.0%$-2.20n/a
September 30, 2025$2.8B5.0%$-0.09n/a
June 30, 2025$2.8B4.3%$0.18n/a
March 31, 2025$2.6B5.4%$0.25n/a
December 31, 2024$2.8B0.9%$-1.00n/a

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

12 ledger entries and 68 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.